The Germany-based company submitted studies to federal regulators saying Spiriva decreases side effects of chronic obstructive pulmonary disease, such as coughing, wheezing and shortness of breath. Spiriva is co-marketed in the U.S. by the world’s largest drug maker, Pfizer Inc.
About EQUITIES:
Since 1951, EQUITIES Magazine has been a leading media company providing business editorial content designed to serve the needs of business leaders, professionals, institutional investors and retail investors. We are focused on business and the business of making money, not on lifestyle subjects. We publish original reporting in print and on our website, as well as select content at www.nasdaq.com. For 28 years we have hosted our own branded investor conferences that connect public company CEO’s with our loyal readers in the investment community.
Sign up for a free one-year subscription to EQUITIES Magazine
